Phase II Randomized Study of p53 Antisense Oligonucleotide (Cenersen) plus Idarubicin With or Without Cytarabine in Refractory and Relapsed Acute Myeloid Leukemia

Antzeko izenburuak

• Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia
  nork: Schimmer, Aaron D., et al.
  Argitaratua: (2009)
• Safety and Pharmacokinetics of the Antisense Oligonucleotide (ASO) LY2181308 as a Single-Agent or in Combination with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML)
  nork: Erba, Harry P., et al.
  Argitaratua: (2013)
• Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
  nork: Boddu, Prajwal, et al.
  Argitaratua: (2018)
• A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
  nork: Short, Nicholas J., et al.
  Argitaratua: (2017)
• Final Results of a Phase 2, Open-Label Study of Indisulam, Idarubicin and Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
  nork: Assi, Rita, et al.
  Argitaratua: (2018)